A new AI tool, BIOPREVENT, predicts serious post-transplant complications months before symptoms appear using blood biomarkers and clinical data.
Key Details
- 1BIOPREVENT was developed by MUSC Hollings Cancer Center and validated with data from 1,310 transplant recipients.
- 2The tool outperformed standard clinical models in predicting chronic graft-versus-host disease (GVHD) and transplant-related death.
- 3BIOPREVENT uses seven immune protein biomarkers and nine clinical factors to assess risk.
- 4Predictions were validated in an independent patient cohort, showing reliable risk stratification up to 18 months post-transplant.
- 5A free, web-based application is available for clinicians to use the tool for research and risk assessment.
Why It Matters
Early identification of high-risk transplant patients can enable closer monitoring and potential intervention before severe complications arise, representing a significant advance in personalized medicine using AI and biomarker data. This AI tool sets a precedent for broader use of machine learning models to improve outcomes in complex medical scenarios requiring longitudinal risk prediction.
Source
EurekAlert
Related News
•EurekAlert
AI System Enhances Cancer Cell Detection via Light Scattering Spectra
Japanese researchers developed an AI system using light scattering spectra to improve cancer cell identification in cytology.
•EurekAlert
AI and X-ray Imaging Reveal Lost Texts in Ancient Roman Scrolls
AI and x-ray technology enable scientists to virtually read previously unreadable, carbonized Roman scrolls from Herculaneum.
•EurekAlert
AI’s Potential to Expand, Not Shrink, the Clinical Workforce
AI advancements may lead to more, not fewer, healthcare jobs, challenging common fears about workforce reductions in specialties like radiology.